期刊文献+

一种基于绿色荧光蛋白的蛋白酶体抑制剂细胞筛选模型 被引量:4

Establishment of a GFP-based cellular model for screening novel proteasome inhibitors
原文传递
导出
摘要 为建立基于绿色荧光蛋白(GFP)的药物筛选模型,并用此模型从包括中药提取物在内的化合物中筛选新型蛋白酶体抑制剂,本研究构建了pGC-E1-ZU1-GFP融合蛋白慢病毒表达载体并感染A549细胞,筛选稳定表达细胞株,用已知蛋白酶体抑制剂PS-341处理细胞,荧光显微镜检测处理前后细胞GFP水平变化。结果获得了稳定表达pGC-E1-ZU1-GFP的A549细胞,这些细胞用PS-341处理24h后用荧光显微镜检测,发现细胞绿色荧光强度相对于对照组明显增强。利用这一模型对一些化合物进行筛查,发现了一些新的蛋白酶体抑制剂。 To establish a green fluorescent protein (GFP)-based cellular model for screening proteasome inhibitors from compounds including extracts from Traditional Chinese Medicinal herbs, we transfected A549 cells with lentivirus expression vector pGC-E1-ZU1-GFP, and selected clones stably expressing ZU1-GFP. The A549-ZU1-GFP cells were treated with PS-341 for 24 h, and the accumulation of GFP was analyzed by fluorescence microscope. We found that the fluorescence intensity of A549-ZU1-GFP cells treated with PS-341 was significantly increased as compared to the control. We screened for proteasome inhibitors from compounds including some from Traditional Chinese Medicinal herbs, and the data suggested a few compounds could be novel proteasome inhibitors.
出处 《生物工程学报》 CAS CSCD 北大核心 2009年第3期452-456,共5页 Chinese Journal of Biotechnology
基金 国家自然科学基金项目(No.30871110) 中国科学院知识创新工程重要方向项目(No.KSCX1-YW-R-26) 广东省自然科学基金重点项目(No.06107503) 广东省科技计划项目(No.2007B030701005) 国家高技术研究发展计划(863计划)(No.2006AA02A301)资助~~
关键词 蛋白酶体抑制剂 筛选模型 绿色荧光蛋白 proteasome inhibitor, screening model, green fluorescent protein
  • 相关文献

参考文献1

二级参考文献18

  • 1Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modem medicine.Berlin: Springer-Verlag. 1992:817-847.
  • 2Qinghaosu antimalaria coordinating research group. Antimalaria studies on Qinghaosu. Chin Med J (Engl) 1979; 92:811-816.
  • 3Woodrow C J, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005; 81:71-78.
  • 4Li SZ. The compendium ofmateria medica (Originally published in the Ming Dynasty of China, 1578). Beijing: People's Medical Publishing House. 1982.
  • 5Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As203)in the treatment of acute promyelocytic leukemia (APL):Ⅰ. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
  • 6Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with Arsenic Trioxide: remission induction,follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-3324.
  • 7Shen ZX, Chen GQ, Ni JH, et al.Use of arsenic trioxide (As2O3)in the treatment of acute promyelocytic leukemia (APL): Ⅱ.Clinical efficacy and pharmacokinetics in relapsed patients.Blood 1997; 89:3354-3360.
  • 8Sun HD, Ma L, Hu XC, Zhang TD. Ai-Lin Ⅰ treated 32 cases ofacute promyelocytic leukemia. Chin J Integrat Chin West Med 1992; 12:170-171.
  • 9Fujita E, Fujita T, Katayarna H, Shibuya M. Terpenoids. Part ⅩⅤ.Structure and absolute configuration of oridonin isolated from Isodonjaponicus trichocarpus. J Chem Soc (Chem Comm) 1970;21:1674-1681.
  • 10Henan Medical Institute, Henan Medical College, Yunnan Institute of Botany. Oridonin--a new antitumor subject. Chin Science Bull 1978; 23:53-56.

共引文献9

同被引文献45

  • 1吴瑞,张树珍.绿色荧光蛋白及其在植物分子生物学中的应用[J].分子植物育种,2005,3(2):240-244. 被引量:20
  • 2郝丽梅,李唐棣,梅兴国.红色荧光蛋白的研究进展[J].国外医学(药学分册),2006,33(2):131-133. 被引量:17
  • 3单志新,林秋雄,符永恒,邓春玉,李晓红,余细勇.用绿色荧光蛋白(GFP)作为报告分子筛选有效的siRNA[J].中国生物化学与分子生物学报,2007,23(3):231-235. 被引量:12
  • 4Sun XM, Butterworth M, MacFarlane M, et al. Caspase activation inhibits proteasome function during apoptosis. Mol Cell, 2004, 14(1): 81-93.
  • 5Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol, 2005, 6(1): 79-86.
  • 6Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ, 1999, 6(4): 303-313.
  • 7Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA, 1998, 95(6): 2727-2730.
  • 8Peterson LF, Boyapati A, Ahn EY, et al. Acute myeloid leukemia with the 8q22; 21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 2007, 110(3): 799-805.
  • 9Wang JX, Hoshino T, Redner RL, et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/ HDAC1 complex. Proc Natl Acad Sci USA, 1998, 95(18): 10860-10865.
  • 10Amann JM, Nip J, Strom DK, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol, 2001, 21(19): 6470-6483.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部